Unknown

Dataset Information

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.


ABSTRACT:

Rationale & objective

Information regarding disparities in initiating sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) in patients with chronic kidney disease (CKD) is limited. We examined sociodemographic and clinical factors associated with the initiation of SGLT2i, GLP-1RA, or second-generation sulfonylureas in a Medicare Fee-For-Service patient population with CKD and type 2 diabetes.

Study design

Retrospective cohort study.

Setting & participants

The 20% random sample of Medicare Fee-For-Service claims, 2012-2018.

Exposures

Patients' sociodemographic and clinical factors.

Outcomes

Use of SGLT2i, GLP-1RA, or sulfonylureas.

Analytical approach

Patients with a newly initiated prescription

SUBMITTER: Zhao JZ 

PROVIDER: S-EPMC9803841 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature